This Phase III clinical trial is for patients with non-operable, progressive and/or recurrent glioblastoma multiforme. To find out if you might be eligible to participate in this study, please review the inclusion and exclusion criteria outlined below. However, please contact a trial centre for more information about the trial and eligibility requirements, and discuss with your doctor before beginning any treatment.

INCLUSION CRITERIA INCLUDE (BUT ARE NOT LIMITED TO):
• Male or female at least 18 years of age
• Diagnosed GBM
• Progressive and/or recurrent GBM after conventional therapy
• Patient is not considered a candidate for surgery
• Karnofsky Performance Score 70-100
• Tumour characteristic must be:
      • Unifocal
      • Unilateral
      • Lesion diameter equal to or greater than 1.0 cm and equal to or less than 4.0 cm

EXCLUSION CRITERIA INCLUDE (BUT ARE NOT LIMITED TO):
• Chemotherapy within 30 days prior to study entry, or nitrosoureas or Mitomycin-C therapy within 42 days prior to study entry
• Radiotherapy or stereotactic (gamma knife) radiosurgery within 90 days prior to study entry
• Tumour surgery, tumour debulking or other neurosurgery procedure within 30 days prior to study entry